RT Journal Article
SR Electronic
T1 Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40 mg o.d. <em>vs</em> 40 mg b.i.d. The X-COVID19 Randomized Clinical Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.17.21266488
DO 10.1101/2021.11.17.21266488
A1 Morici, Nuccia
A1 Podda, GianMarco
A1 Birocchi, Simone
A1 Bonacchini, Luca
A1 Merli, Marco
A1 Trezzi, Michele
A1 Massaini, Gianluca
A1 Agostinis, Marco
A1 Carioti, Giulia
A1 Serino, Francesco Saverio
A1 Gazzaniga, Gianluca
A1 Barberis, Daniela
A1 Antolini, Laura
A1 Valsecchi, Maria Grazia
A1 Cattaneo, Marco
YR 2021
UL http://medrxiv.org/content/early/2021/11/21/2021.11.17.21266488.abstract
AB It is uncertain whether higher doses of anticoagulants than recommended for thromboprophylaxis are necessary in COVID-19 patients hospitalized in general wards. This is a multicentre, open-label, randomized trial performed in 9 Italian centres, comparing 40 mg b.i.d. vs 40 mg o.d. enoxaparin in COVID-19 patients, between April 30, 2020 and April 25, 2021. Primary efficacy outcome was in-hospital incidence of venous thromboembolism (VTE): asymptomatic or symptomatic proximal deep vein thrombosis (DVT) diagnosed by serial compression ultrasonography (CUS), and/or symptomatic pulmonary embolism (PE) diagnosed by computed tomography angiography (CTA). Secondary endpoints included each individual component of the primary efficacy outcome and a composite of death, VTE, mechanical ventilation, stroke, myocardial infarction, admission to ICU. Safety outcomes included major bleeding. The study was interrupted prematurely due to slow recruitment. We included 183 (96%) of the 189 enrolled patients in the primary analysis (91 in b.i.d., 92 in o.d.). Primary efficacy outcome occurred in 6 patients (6·5%, 0 DVT, 6 PE) in the o.d. group and 0 in the b.id. group (ARR 6·5, 95% CI, 1·5-11·6). Absence of concomitant DVT and imaging characteristics suggest that most pulmonary artery occlusions were actually caused by local thrombi rather than PE. Statistically non-significant differences in secondary and safety endpoints were observed, with two major bleeding events in each arm. In conclusion, no DVT developed in COVID-19 patients hospitalized in general wards, independently of enoxaparin dosing used for thromboprophylaxis. Pulmonary artery occlusions developed only in the o.d. group. Our trial is underpowered and with few events.REGISTRATION ClinicalTrials.gov Identifier: NCT04366960Ethics Commettee approvation number 75/2020Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov Identifier: NCT04366960Funding StatementItalfarmaco. The funding source had no roles in study design, data collection, data access, data analysis, data interpretation, decision to writing of the report and submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ASST Grande Ospedale Metropolitano Niguarda gave ethical approval for this work. Ethics Commettee approvation number: 75/2020I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors